The tools we use in research should reflect the full spectrum of genetic diversity, but they often do not. This is a gap that an international team of scientists is exploring through the lens of induced pluripotent stem cell (iPSC) lines. iPSCs are a type...
Receiving a heart transplant is a life-changing journey, and you may be wondering about your treatment options. This is why The Heart Hub is excited to introduce A Hearts Journey: A Patient & Caregiver Guide to Heart Transplant. This brand-new, interactive...
On March 5, 2025, The Hospital for Sick Children (SickKids) received a significant breakthrough in pediatric research with an $11.7 million award from Genome Canada. As part of the Canadian Precision Health Initiative, a total of $81 million in...
After eight transformative years at the Ted Rogers Centre for Heart Research (TRCHR), Dr. Soror Sharifpoor is embarking on an exciting new chapter in her career. As the Director of Strategy & Translation at the Translational Biology and Engineering Program (TBEP)...
With a mission to support novel approaches to managing and preventing heart failure, the Ted Rogers Centre for Heart Research uses its Innovation Fund to propel emerging research with great potential. The 2024-25 Innovation Fund Seed Grants are currently open and you...
The Ted Rogers Centre for Heart Research is delighted to welcome Iris Cohn as the new Innovator in Genomic Translation - also recently promoted to Director of the Pharmacogenetics (PGx) Program at The Hospital for Sick Children. A trained pharmacist, Iris established...
Dilated cardiomyopathy (DCM) is one of the most common inherited heart diseases – but we don’t know why.
Afflicting as many as one in five Canadians, DCM occurs when a functioning heart muscle begins to dilate, or stretch, for no apparent reason. This enlarged heart can no longer maintain its normal rhythm and pump the blood around the body, which leads to heart failure. While we know that some forms of DCM are rooted in genetics, its molecular culprits remain poorly understood.
A new study from the Ted Rogers Centre has revealed widespread differences in protein biochemistry between healthy and diseased hearts. In so doing, it expands our understanding of heart physiology and opens the door for ideas to improve detection and treatment of DCM.
The paper was published in the Proceedings of the National Academy of Sciences of the U.S.A in November 2016.
Led by Ted Rogers Centre Education Fund recipient Uros Kuzmanov, the research team mapped changes in protein signalling pathways in heart cells that lead to DCM. Specifically, in a mouse model of the disease, they measured protein “phosphorylation” in heart tissue – a biochemical reaction where a phosphate group is added onto a protein to make it more, or less, active, or to change its position in the cell, or to mark it for destruction.
Via this phosphoproteomic method, they were able to study how sick hearts activate or dampen entire protein signalling pathways – and in so doing, become vulnerable to heart failure. No such study had yet been accomplished at this level of scale in the study of DCM.
The research team uncovered hundreds of signalling pathways that went off course in DCM hearts. They generated the very first comprehensive map of molecular signaling events – including those unexpected – that go awry in heart failure.
What’s next: similar analyses in human tissue. If, as expected, they detect similar signalling changes, a human map could lead to promising new drug targets or biomarkers for early detection.
“We expect to be able to detect specific changes in signalling pathways in different cardiac patients,” said Kuzmanov.
“And our approach is not limited to the DCM — it could be applied to all heart disease.”
